Terminated PHASE2 INTERVENTIONAL NCT00104806

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Interventions arsenic trioxide cholecalciferol

Updated 8 times since 2017 Last updated: Aug 8, 2018 Started: Nov 30, 2004 Primary completion: Jan 31, 2006 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

sponsor discontinues support

A PHASE2 clinical study on Leukemia and Myelodysplastic Syndromes, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE2
Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Terminated PHASE2
Jul 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Jul 2017 [monthly]

Terminated PHASE2

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Wake Forest University Health Sciences

Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winston-Salem, United States